GLEN LILLY: Open Payments
NPI 1275935934 · HOLLYWOOD, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$384 in 18 payments from 9 companies in 2025. Trend: 2023 $595 · 2024 $666 · 2025 $384
Food & beverage: $384
| Company | Payments | Amount |
|---|---|---|
| Lilly USA, LLC | 5 | $111 |
| Corcept Therapeutics | 2 | $55 |
| ABBVIE INC. | 3 | $53 |
| Janssen Biotech, Inc. | 2 | $47 |
| Phathom Pharmaceuticals, Inc. | 2 | $36 |
| AstraZeneca Pharmaceuticals LP | 1 | $25 |
| RECORDATI_RARE_DISEASES_INC. | 1 | $20 |
| Alexion Pharmaceuticals, Inc. | 1 | $19 |
| Amgen Inc. | 1 | $18 |
Products named: MOUNJARO, Korlym, VRAYLAR, TREMFYA, VOQUEZNA, JARDIANCE, AIRSUPRA, ISTURISA.
Industry payments across MD — which companies pay providers there.
